## Jeremy B Sussman

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/3428855/publications.pdf

Version: 2024-02-01

80 papers

3,229 citations

236612 25 h-index 54 g-index

85 all docs 85 docs citations

85 times ranked 5615 citing authors

#	Article	IF	Citations
1	Data-Tracking on Government, Non-profit, and Commercial Health-Related Websites. Journal of General Internal Medicine, 2022, 37, 1315-1317.	1.3	6
2	Data-Tracking Among Digital Pharmacies. Annals of Pharmacotherapy, 2022, 56, 958-962.	0.9	4
3	Dashboards in Health Care Settings: Protocol for a Scoping Review. JMIR Research Protocols, 2022, 11, e34894.	0.5	11
4	Maintaining Implementation through Dynamic Adaptations (MIDAS): protocol for a cluster-randomized trial of implementation strategies to optimize and sustain use of evidence-based practices in Veteran Health Administration (VHA) patients. Implementation Science Communications, 2022, 3, 53.	0.8	0
5	Failure of Cardiovascular Phase 3 Randomized Clinical Trials to Report Pre-trial and Post-trial Parameters: a Cross-sectional Analysis of ClinicalTrials.gov. Journal of General Internal Medicine, 2021, 36, 1808-1810.	1.3	2
6	CT Measured Cortical Volume Ratio Is an Accurate Alternative to Nuclear Medicine Split Scan Ratio Among Living Kidney Donors. Transplantation, 2021, Publish Ahead of Print, 2596-2605.	0.5	1
7	Sex Differences in Cognitive Decline Among US Adults. JAMA Network Open, 2021, 4, e210169.	2.8	171
8	Understanding providers' attitudes and key concerns toward incorporating CVD risk prediction into clinical practice: a qualitative study. BMC Health Services Research, 2021, 21, 561.	0.9	6
9	Chronologic Bias, Confounding by Indication, and COVID-19 Care. Chest, 2021, 160, e86-e87.	0.4	1
10	Prevalence of Third-Party Data Tracking by US Hospital Websites. JAMA Network Open, 2021, 4, e2126121.	2.8	6
11	Testing Practices, Interpretation, and Diagnostic Evaluation of Iron Deficiency Anemia by US Primary Care Physicians. JAMA Network Open, 2021, 4, e2127827.	2.8	6
12	Predicting clinically significant response to primary care treatment for depression from electronic health records of veterans. Journal of Affective Disorders, 2021, 294, 337-345.	2.0	1
13	A Method to Quantify Mean Hypertension Treatment Daily Dose Intensity Using Health Care System Data. JAMA Network Open, 2021, 4, e2034059.	2.8	9
14	Optimal cholesterol treatment plans and genetic testing strategies for cardiovascular diseases. Health Care Management Science, 2021, 24, 1-25.	1.5	8
15	Using Longitudinal Health Records to Simulate the Impact of National Treatment Guidelines for Cardiovascular Disease., 2021,,.		2
16	The Impact of Age on the Likely Impact of Coronary Calcium Testing in the 2018 Cholesterol Guidelines. Journal of General Internal Medicine, 2020, 35, 386-388.	1.3	0
17	Research Waste in Randomized Clinical Trials: a Cross-Sectional Analysis. Journal of General Internal Medicine, 2020, 35, 3105-3107.	1.3	6
18	Postcritical illness vulnerability. Current Opinion in Critical Care, 2020, 26, 500-507.	1.6	5

#	Article	IF	CITATIONS
19	Identifying Recommendations for Stopping or Scaling Back Unnecessary Routine Services in Primary Care. JAMA Internal Medicine, 2020, 180, 1500.	2.6	19
20	Validation of a Health System Measure to Capture Intensive Medication Treatment of Hypertension in the Veterans Health Administration. JAMA Network Open, 2020, 3, e205417.	2.8	4
21	Association Between Blood Pressure and Later-Life Cognition Among Black and White Individuals. JAMA Neurology, 2020, 77, 810.	4.5	56
22	Smarter Use of Corticosteroids in Treating Patients with Septic Shock. JAMA Network Open, 2020, 3, e2029323.	2.8	3
23	Abstract WP495: Sex Differences in Cognitive Decline: A Pooled Cohort Analysis of ARIC, CARDIA, CHS, FOS, NOMAS. Stroke, 2020, 51, .	1.0	0
24	Optimal coinsurance rates for a heterogeneous population under inequality and resource constraints. IISE Transactions, 2019, 51, 74-91.	1.6	6
25	Hispanic representation in diabetes cardiovascular outcomes trials. BMJ Open Diabetes Research and Care, 2019, 7, e000656.	1.2	7
26	Increased Cardiovascular Disease Risk in Veterans With Mental Illness. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005563.	0.9	19
27	Serum NfL (Neurofilament Light Chain) Levels and Incident Stroke in Adults With Diabetes Mellitus. Stroke, 2019, 50, 1669-1675.	1.0	60
28	A Simulation Model to Evaluate the Implications of Genetic Testing in Cholesterol Treatment Plans. , 2019, , .		1
29	Estimation of global insulin use for type 2 diabetes, 2018–30: a microsimulation analysis. Lancet Diabetes and Endocrinology,the, 2019, 7, 25-33.	5.5	138
30	Annals On Call - Statins for Primary Prevention: Finding the Balance. Annals of Internal Medicine, 2019, 170, OC1.	2.0	0
31	An Examination of Deintensification Recommendations in Clinical Practice Guidelines. JAMA Internal Medicine, 2018, 178, 414.	2.6	13
32	Validation of Risk Equations for Complications of Type 2 Diabetes (RECODe) Using Individual Participant Data From Diverse Longitudinal Cohorts in the U.S Diabetes Care, 2018, 41, 586-595.	4.3	62
33	Overtreatment and Deintensification of Diabetic Therapy among Medicare Beneficiaries. Journal of General Internal Medicine, 2018, 33, 34-41.	1.3	36
34	Of Barbershops and Churches. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e005149.	0.9	3
35	Quality Improvement and Personalization for Statins: the QUIPS Quality Improvement Randomized Trial of Veterans' Primary Care Statin Use. Journal of General Internal Medicine, 2018, 33, 2132-2137.	1.3	7
36	Generalizing Intensive Blood PressureÂTreatment to Adults With DiabetesÂMellitus. Journal of the American College of Cardiology, 2018, 72, 1214-1223.	1.2	7

#	Article	IF	CITATIONS
37	Clinical Implications of Revised Pooled Cohort Equations for Estimating Atherosclerotic Cardiovascular Disease Risk. Annals of Internal Medicine, 2018, 169, 20.	2.0	151
38	Designing for Clinical Change: Creating an Intervention to Implement New Statin Guidelines in a Primary Care Clinic. JMIR Human Factors, 2018, 5, e19.	1.0	5
39	Corrected ROC analysis for misclassified binary outcomes. Statistics in Medicine, 2017, 36, 2148-2160.	0.8	11
40	Detecting Heterogeneous Treatment Effects to Guide Personalized Blood Pressure Treatment. Annals of Internal Medicine, 2017, 166, 354.	2.0	35
41	The Veterans Affairs Cardiac Risk Score. Medical Care, 2017, 55, 864-870.	1.1	24
42	Development and validation of Risk Equations for Complications Of type 2 Diabetes (RECODe) using individual participant data from randomised trials. Lancet Diabetes and Endocrinology,the, 2017, 5, 788-798.	5 <b>.</b> 5	134
43	Effects of Guideline and Formulary Changes on Statin Prescribing in the Veterans Affairs. Health Services Research, 2017, 52, 1996-2017.	1.0	8
44	Implications of True and Perceived Treatment Burden on Cardiovascular Medication Use. MDM Policy and Practice, 2017, 2, 238146831773530.	0.5	3
45	Black-White Cardiovascular Disease Disparities After Target-Based Versus Personalized Benefit–Based Lipid and Blood Pressure Treatment. MDM Policy and Practice, 2017, 2, 238146831772574.	0.5	3
46	Benefit and harm of intensive blood pressure treatment: Derivation and validation of risk models using data from the SPRINT and ACCORD trials. PLoS Medicine, 2017, 14, e1002410.	3.9	60
47	New Studies Do Not Challenge the American College of Cardiology/American Heart Association Lipid Guidelines. Annals of Internal Medicine, 2016, 164, 683.	2.0	8
48	Data-Driven Markov Decision Process Approximations for Personalized Hypertension Treatment Planning. MDM Policy and Practice, 2016, 1, 238146831667421.	0.5	13
49	Age Disparities in the Use of Steroid-sparing Therapy for Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2016, 22, 1923-1928.	0.9	29
50	Alternative Strategies to Achieve Cardiovascular Mortality Goals in China and India. Circulation, 2016, 133, 840-848.	1.6	22
51	Reply: Risk-based Heterogeneity of Treatment Effect in Trials and Implications for Surveillance of Clinical Effectiveness Using Regression Discontinuity Designs. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1399-1400.	2.5	0
52	Three simple rules to ensure reasonably credible subgroup analyses. BMJ, The, 2015, 351, h5651.	3.0	157
53	Stress Testing Before Low-Risk Surgery. JAMA Internal Medicine, 2015, 175, 645.	2.6	31
54	Comparing the effectiveness of competing tests for reducing colorectal cancer mortality: a network meta-analysis. Gastrointestinal Endoscopy, 2015, 81, 700-709.e3.	0.5	48

#	Article	IF	CITATIONS
55	Implications of Heterogeneity of Treatment Effect for Reporting and Analysis of Randomized Trials in Critical Care. American Journal of Respiratory and Critical Care Medicine, 2015, 192, 1045-1051.	2.5	204
56	Stress Testing After Percutaneous Coronary Intervention in the Veterans Affairs HealthCare System. Circulation: Cardiovascular Quality and Outcomes, 2015, 8, 486-492.	0.9	10
57	Improving diabetes prevention with benefit based tailored treatment: risk based reanalysis of Diabetes Prevention Program. BMJ, The, 2015, 350, h454-h454.	3.0	101
58	The Potential Impact of Intelligent Systems for Mobile Health Self-Management Support: Monte Carlo Simulations of Text Message Support for Medication Adherence. Annals of Behavioral Medicine, 2015, 49, 84-94.	1.7	24
59	Rates of Deintensification of Blood Pressure and Glycemic Medication Treatment Based on Levels of Control and Life Expectancy in Older Patients With Diabetes Mellitus. JAMA Internal Medicine, 2015, 175, 1942.	2.6	137
60	Effect of Patients' Risks and Preferences on Health Gains With Plasma Glucose Level Lowering in Type 2 Diabetes Mellitus. JAMA Internal Medicine, 2014, 174, 1227.	2.6	158
61	Evidence-Based Risk Communication. Annals of Internal Medicine, 2014, 161, 270.	2.0	310
62	Rethinking the Frequency of Between-Visit Monitoring for Patients With Diabetes. Medical Care, 2014, 52, 511-518.	1.1	9
63	Enhancing Patient-Centered Care: SGIM and Choosing Wisely. Journal of General Internal Medicine, 2014, 29, 432-433.	1.3	13
64	Cardiovascular outcome trials of glucose-lowering strategies in type 2 diabetes. Lancet, The, 2014, 384, 1095.	6.3	0
65	Using Benefit-Based Tailored Treatment to Improve the Use of Antihypertensive Medications. Circulation, 2013, 128, 2309-2317.	1.6	80
66	Time to Stroke Magnetic Resonance Imaging. Journal of Stroke and Cerebrovascular Diseases, 2013, 22, 784-791.	0.7	6
67	At the "Heart―of Inflammatory Bowel Diseases. Gastroenterology, 2013, 145, 1486-1488.	0.6	2
68	Providing clinicians with a patient's 10-year cardiovascular risk improves their statin prescribing: a true experiment using clinical vignettes. BMC Cardiovascular Disorders, 2013, 13, 90.	0.7	14
69	Improving the Reliability of Physician "Report Cards― Medical Care, 2013, 51, 266-274.	1.1	14
70	Improved Cardiovascular Risk Prediction Using Nonparametric Regression and Electronic Health Record Data. Medical Care, 2013, 51, 251-258.	1.1	52
71	Maximizing the Value of Mobile Health Monitoring by Avoiding Redundant Patient Reports: Prediction of Depression-Related Symptoms and Adherence Problems in Automated Health Assessment Services. Journal of Medical Internet Research, 2013, 15, e118.	2.1	12
72	Effect of Perioperative Statins on Death, Myocardial Infarction, Atrial Fibrillation, and Length of Stay. Archives of Surgery, 2012, 147, 181.	2.3	104

#	Article	IF	CITATIONS
73	Cardiac risk is not associated with hypertension treatment intensification. American Journal of Managed Care, 2012, 18, 414-20.	0.8	1
74	Examining the Evidence: A Systematic Review of the Inclusion and Analysis of Older Adults in Randomized Controlled Trials. Journal of General Internal Medicine, 2011, 26, 783-790.	1.3	324
75	Inclusion and Analysis of Older Adults in RCTs. Journal of General Internal Medicine, 2011, 26, 832-832.	1.3	2
76	Individual and Population Benefits of Daily Aspirin Therapy. Circulation: Cardiovascular Quality and Outcomes, 2011, 4, 268-275.	0.9	30
77	Validation of triage criteria for deciding which apparently inebriated persons require emergency department care. Emergency Medicine Journal, 2011, 28, 579-584.	0.4	12
78	Hospitals during recession and recovery: Vulnerable institutions and quality at risk. Journal of Hospital Medicine, 2010, 5, 302-305.	0.7	14
79	An IV for the RCT: using instrumental variables to adjust for treatment contamination in randomised controlled trials. BMJ: British Medical Journal, 2010, 340, c2073-c2073.	2.4	151
80	Evolutionary Control of Infectious Disease: Prospects for Vectorborne and Waterborne Pathogens. Memorias Do Instituto Oswaldo Cruz, 1998, 93, 567-576.	0.8	16